ERBB2 and metastatic malignant neoplasm in the lymph nodes: In conclusion, HRD-low subgroup of patients with HER2-low EBC has a better survival prognosis in the TCGA, SYSU, and FUSCC cohorts, especially in patients with HR positive or fewer lymph node metastases.